FindTrial
Sign In

Studio CARUSO (CARotid plaqUe StabilizatiOn and regression with evolocumab): stabilizzazione morfologica e regressione della placca carotidea con evolocumab

Status
Not yet recruiting
Phases
Phase 4
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-518566-27-00
Acronym
CARUSO
Enrollment
100
Registered
2025-01-29
Start date
Unknown
Completion date
Unknown
Last updated
2025-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

carotid stenosis

Brief summary

Superiority of evolocumab added to ongoing LLT versus ongoing LLT in determining morphological stabilization and carotid plaque regression, at 6 and 12 months, respectively

Interventions

DRUGRepatha 140 mg solution for injection in pre-filled syringe

Sponsors

Azienda Ospedaliera Ordine Mauriziano Di Torino
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Superiority of evolocumab added to ongoing LLT versus ongoing LLT in determining morphological stabilization and carotid plaque regression, at 6 and 12 months, respectively—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026